Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Woman throwing punch at punching bag.

Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics

(As of December 31, 2021)

  • $148M

    FY’21 Revenue

    13% YtY Growth

    (10% organic)

  • 23%

    YtY growth (FY'21)

    Joint Preservation and Restoration

    (12% organic)

  • #1

    U.S. Market Share

    OA Pain Management

  • $94M

    Cash balance
    with no debt

Recent News
Anika Announces First Surgeries Performed Using the X-Twist™ Fixation System and Commences Limited Market Release
Sep 12, 2022

BEDFORD, Mass., September 12, 2022-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the limited market...

Anika Reports Second Quarter Fiscal 2022 Financial Results
Aug 3, 2022

BEDFORD, Mass., August 3, 2022 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its second...

Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine
Jul 27, 2022

BEDFORD, Mass., July 27, 2022 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the...

All Press Releases

Featured Event
Q2 2022 Anika Therapeutics Earnings Conference Call
Wednesday, August 3, 2022
5:00pm - 6:00pm EDT

See All Events

Current Investor Presentation

View PresentationView More
Investor Day 2021

View Presentation

Investor Contacts

Primary IR Contact

  • Mark Namaroff

    Vice President, Investor Relations, ESG, and Corporate Communications

    Anika Therapeutics, Inc.

    Phone: (781) 457-9287

    Email: investorrelations@anika.com

  • Transfer Agent

    American Stock Transfer & Trust Co.

    59 Maiden Lane

    New York, NY 10038

    Phone: (718) 921-8261

Want Alerts? Sign up for alerts and never miss an Investor update!

Subscribe

To Top